<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209807</url>
  </required_header>
  <id_info>
    <org_study_id>PFD-ESC</org_study_id>
    <nct_id>NCT00209807</nct_id>
  </id_info>
  <brief_title>Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder</brief_title>
  <official_title>Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <brief_summary>
    <textblock>
      Patients with major depressive disorder (MDD) commonly have many gastrointestinal complaints.
      Gastrointestinal pain is classified into 2 categories: visceral and somatic pain. The main
      aim of this study is to compare somatic and visceral sensitivity between healthy people and
      pateints with MDD. These two sensitivities will be assessed by the 2 following tests:
      standardized rectal distension and Transdermal transcutaneous electric nerve stimulation.
      Thereafter, patients with MDD will be randomly allocated to escitalopram or reboxetine. After
      6 weeks of treatment, somatic and visceral sensitivity will be reassessed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rectal distension Transcutaneous Electrical Neuro-Stimulation</measure>
    <time_frame>1-7 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Major Depression</condition>
  <condition>Pain</condition>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with MDD randomized to Escitalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MDD patients receiving reboxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volonteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>escitalopram 10 mg/d for 6 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>reboxetine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reboxetine</intervention_name>
    <description>Reboxetine 8 mg/d for 6 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This group of healthy volonteers will receive no drug and will be a healthy comparator.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MDD according with DSM-IV-TR

          -  Hamilton depression scale &gt; 21

        Exclusion Criteria:

          -  history of gastrointestinal illness

          -  history of escitalopram, citalopram or reboxetine allergy.

          -  history of escitalopram, citalopram or reboxetine resistant depression.

          -  other axis I psychiatric disorder.

          -  a punctuation &gt; 2 on the suicide item of the Ham-D.

          -  history of ECT during the past 6 months.

          -  pharmacological failure of the present depressive episode.

          -  pregnancy or nursing.

          -  treatment with drugs that may interact with study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Casas Miguel, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Vall d'Hebron Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Antoni Ramos-Quiroga, MD</last_name>
      <phone>0034 93 489 42 94</phone>
      <email>jaramos@vhebron.net</email>
    </contact>
    <contact_backup>
      <last_name>Xavier Castells, MD</last_name>
      <phone>0034 93 489 42 94</phone>
      <email>xcc@icf.uab.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Miguel Casas, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Antoni Ramos-Quiroga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan-R Malagelada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Azpiroz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosa Bosch Munso</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Parramon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Castells Cervelló, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Accarino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Serra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Miguel Casas Brugué</name_title>
    <organization>Servei de Psiquiatria. Hospital Universitari Vall d'Hebron</organization>
  </responsible_party>
  <keyword>major depression</keyword>
  <keyword>pain</keyword>
  <keyword>escitalopram</keyword>
  <keyword>reboxetine</keyword>
  <keyword>visceral sensitivity</keyword>
  <keyword>somatic sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Reboxetine</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

